109 related articles for article (PubMed ID: 11830755)
1. Toxicity of Glycyl-l-Prolyl-l-Glutamate Pseudotripeptides: Cytotoxic, Oxidative, Genotoxic, and Embryotoxic Perspectives.
Turkez H; Ozdemir Tozlu O; Tatar A; Arslan ME; Cadirci K; Marinelli L; Yapca OE; Cacciatore I; Di Stefano A; Mardinoglu A
J Toxicol; 2022; 2022():3775194. PubMed ID: 36444193
[TBL] [Abstract][Full Text] [Related]
2. Repurposing Cholinesterase Inhibitors as Antidepressants? Dose and Stress-Sensitivity May Be Critical to Opening Possibilities.
Fitzgerald PJ; Hale PJ; Ghimire A; Watson BO
Front Behav Neurosci; 2020; 14():620119. PubMed ID: 33519395
[TBL] [Abstract][Full Text] [Related]
3. Histidyl-Proline Diketopiperazine Isomers as Multipotent Anti-Alzheimer Drug Candidates.
Turkez H; Cacciatore I; Arslan ME; Fornasari E; Marinelli L; Di Stefano A; Mardinoglu A
Biomolecules; 2020 May; 10(5):. PubMed ID: 32397415
[TBL] [Abstract][Full Text] [Related]
4. The current agonists and positive allosteric modulators of
Yang T; Xiao T; Sun Q; Wang K
Acta Pharm Sin B; 2017 Nov; 7(6):611-622. PubMed ID: 29159020
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs.
Ramsay RR; Tipton KF
Molecules; 2017 Jul; 22(7):. PubMed ID: 28714881
[TBL] [Abstract][Full Text] [Related]
6. The role of phytochemicals in the treatment and prevention of dementia.
Howes MJ; Perry E
Drugs Aging; 2011 Jun; 28(6):439-68. PubMed ID: 21639405
[TBL] [Abstract][Full Text] [Related]
7. The effects of huperzine A and IDRA 21 on visual recognition memory in young macaques.
Malkova L; Kozikowski AP; Gale K
Neuropharmacology; 2011 Jun; 60(7-8):1262-8. PubMed ID: 21185313
[TBL] [Abstract][Full Text] [Related]
8. Increasing hippocampal acetylcholine levels enhance behavioral performance in an animal model of diencephalic amnesia.
Roland JJ; Mark K; Vetreno RP; Savage LM
Brain Res; 2008 Oct; 1234():116-27. PubMed ID: 18706897
[TBL] [Abstract][Full Text] [Related]
9. Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer's disease.
Van Dam D; Coen K; De Deyn PP
Psychopharmacology (Berl); 2008 Mar; 197(1):37-43. PubMed ID: 18008065
[TBL] [Abstract][Full Text] [Related]
10. Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model.
Van Dam D; Abramowski D; Staufenbiel M; De Deyn PP
Psychopharmacology (Berl); 2005 Jun; 180(1):177-90. PubMed ID: 15654502
[TBL] [Abstract][Full Text] [Related]
11. Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys.
Buccafusco JJ; Terry AV
J Mol Neurosci; 2004; 24(1):85-91. PubMed ID: 15314255
[TBL] [Abstract][Full Text] [Related]
12. Two-year treatment of Alzheimer's disease with eptastigmine. The Eptastigmine Study Group.
Imbimbo BP; Verdelli G; Martelli P; Marchesini D
Dement Geriatr Cogn Disord; 1999; 10(2):139-47. PubMed ID: 10026388
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease.
Imbimbo BP; Martelli P; Troetel WM; Lucchelli F; Lucca U; Thal LJ
Neurology; 1999 Mar; 52(4):700-8. PubMed ID: 10078713
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.
Imbimbo BP
CNS Drugs; 2001; 15(5):375-90. PubMed ID: 11475943
[TBL] [Abstract][Full Text] [Related]
15. An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.
Greig NH; Sambamurti K; Yu QS; Brossi A; Bruinsma GB; Lahiri DK
Curr Alzheimer Res; 2005 Jul; 2(3):281-90. PubMed ID: 15974893
[TBL] [Abstract][Full Text] [Related]
16. Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies.
Braida D; Sala M
CNS Drug Rev; 2001; 7(4):369-86. PubMed ID: 11830755
[TBL] [Abstract][Full Text] [Related]
17. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group.
Canal N; Imbimbo BP
Clin Pharmacol Ther; 1996 Aug; 60(2):218-28. PubMed ID: 8823240
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
